Return to search results.
Complete title: A Phase 1b/2 Study with Gemcitabine and LY2157299 for Patients with Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)
|Research Study Number||20111239|
|Principal Investigator||Andrew Coveler, MD|
Research Study Description
Phase 2a: To compare the overall survival (OS) of patients with Stage II to IV unresectable pancreatic cancer when treated with a combination of LY2157299 and gemcitabine with that of gemcitabine plus placebo.
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Gastrointestinal Cancer; Pancreatic Cancer; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.